METHODS: Therefore, this study translates and culturally adapts the M-CHAT-R/F into Malay and verifies its psychometric properties among the Malaysian population. 500 Malaysian toddlers aged between 18 and 48 months were recruited from different settings. The parents of the toddlers were asked to complete the Malaysian M-CHAT-R/F. The reliability of the screening tool was verified using Cronbach's alpha.
RESULTS: By comparing the screening outcomes of the Malaysian M-CHAT-R/F and clinical evaluation results, the prevalence of ASD was determined as 6.6% in the sample. High values of sensitivity (96.6%) and specificity (93.2%) and a satisfactory positive predictive value (47.5%) supported the validity of the Malaysian M-CHAT-R/F. Furthermore, the receiver operating characteristic analysis yielded three as the optimal cut-off score of the Malaysian M-CHAT-R/F.
DISCUSSION: These results suggest that the Malaysian M-CHAT-R/F is an effective screening tool reliable for use in clinical practice. Further investigation using a representative sample of the whole country is recommended given the high prevalence rate obtained in the current sample.
METHODS: EPICOR Asia (Long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients in Asia) (NCT01361386) is a prospective, multinational, observational study of patients discharged after hospitalization for an ACS, with 2-year follow-up. The aim is to describe short- and long-term (up to 2 years post-index event) AMPs in patients hospitalized for ACS and to record clinical outcomes, healthcare resource use, and self-reported health status. Pre- and in-hospital management, AMPs, and associated outcomes, with particular focus on ischemic and bleeding events, will be recorded during the 2-year follow up.
RESULTS: Between June 2011 and May 2012, 13 005 patients were enrolled. From these, 12 922 patients surviving an ACS (6616 with STEMI, 2570 with NSTEMI, and 3736 with UA) were eligible for inclusion from 219 hospitals across 8 countries and regions in Asia: China (n = 8214), Hong Kong (n = 177), India (n = 2468), Malaysia (n = 100), Singapore (n = 93), South Korea (n = 705), Thailand (n = 957), and Vietnam (n = 208).
CONCLUSIONS: EPICOR Asia will provide information regarding clinical management and AMPs for ACS patients in Asia. Impact of AMPs on clinical outcomes, healthcare resource use, and self-reported health status both during hospitalization and up to 2 years after discharge will also be described.